Hydroquinidine therapy significantly increased the mean temporal burden of ST-segment elevation by 9.4 min/hour compared to baseline in patients with Brugada Syndrome.
Observational (n=10)
No
Does Hydroquinidine affect the burden of ST-segment elevation on 12-lead Holter monitoring in patients with Brugada Syndrome?
10 patients with a confirmed diagnosis of Brugada Syndrome (BrS) and no prior exposure to Quinidine or Hydroquinidine. 90% male, mean age 47±12 years.
Hydroquinidine 300mg oral twice daily for 2 weeks.
Baseline (pre-treatment) assessment using 12-lead 24-hour Holter monitoring.
Change in temporal burden of ST-segment elevation (mean duration in minutes demonstrating diagnostic STE per hour) between baseline and on-treatment.surrogate
In a small pilot study of patients with Brugada Syndrome, Hydroquinidine unexpectedly increased the burden of ST-segment elevation on Holter monitoring and was associated with proarrhythmia in one patient.
Effect estimate: Mean difference 9.4 (95% CI 1.0-17.9)
Absolute Event Rate: 41% vs 31.6%
p-value: p=0.029
Building similarity graph...
Analyzing shared references across papers
Loading...
Kate Chiswell
Julia C. Isbister
Adrienne Kirby
Heart Rhythm O2
The University of Sydney
UNSW Sydney
Macquarie University
Building similarity graph...
Analyzing shared references across papers
Loading...
Chiswell et al. (Fri,) conducted a observational in Brugada Syndrome (n=10). Hydroquinidine vs. Baseline (pre-treatment) was evaluated on Mean temporal burden of ST-segment elevation (min/hr) (Mean difference 9.4, 95% CI 1.0-17.9, p=0.029). Hydroquinidine therapy significantly increased the mean temporal burden of ST-segment elevation by 9.4 min/hour compared to baseline in patients with Brugada Syndrome.
synapsesocial.com/papers/6a025f20c9581ed855361ca2 — DOI: https://doi.org/10.1016/j.hroo.2026.05.001